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Abstract
Background: Chronic stable angina is a leading cause of death worldwide. Danhong injection, a complementary
alternative medicine for chronic stable angina, has been demonstrated to be effective in numerous studies and is
widely prescribed to patients. However, the methodological quality of most prior studies was found to be, in general,
low. Therefore, we designed this randomized controlled trial to evaluate the efficacy and safety of using Danhong
injection to treat chronic stable angina.
Methods/design: This is a randomized multicentre, double-blind, placebo-controlled, adaptive clinical trial. A total of
870 patients meeting the eligibility criteria will be randomly assigned into either the Danhong injection or the
placebo group in a 2:1 ratio. Participants will then undergo a 2-week treatment regimen and a 76-day follow-up
period. Because this is an adaptive trial, two interim analyses are prospectively planned. These will be performed
after one-third and two-thirds of the patients, respectively, have completed the trial. Based on the results of these
interim analyses, a data monitoring committee will determine how to modify aspects of the study without undermining
the validity and integrity of the trial. The primary outcome measure is the proportion of patients who show a clinically
significant change, which is defined as at least a 20-point improvement in angina frequency score on the Seattle Angina
Questionnaire, which will be administered on day 30. Other secondary efficacy and safety outcomes will also be assessed.
Discussion: This trial will provide high-quality evidence regarding the use of Danhong injection to treat chronic
stable angina.
Trial registration: ClinicalTrials.gov: NCT01681316.
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Background
Stable ischaemic heart disease is a leading cause of death
worldwide, and is associated with a substantial and annu-
ally increasing burden on individuals and society [1, 2]. In
the USA, the overall rate of death attributable to cardio-
vascular disease in 2010 was 235.5 per 100,000, and the
total number of inpatient cardiovascular operations and
procedures increased by 28 %, from 5,939,000 in 2000 to
7,588,000 in 2010 [1]. As one of the most common types
of stable ischaemic heart disease, chronic stable angina is
characterized by recurrent chest pain or pressure, known
as angina, which is exacerbated by activity or stress [3].
Despite the continued exploration of myocardial revascu-
larization procedures, preventive therapies, including life-
style interventions, risk factor modification, antiplatelet
therapy [4], renin-angiotensin-aldosterone blocker ther-
apy, and newer anti-anginal drugs [5], some patients still
experience cardiovascular events, and the proportion of
patients whose quality of life is impaired by the frequent
symptoms of this condition remains high [6–8]. This is
thought to be associated with the undesirable side-effects
of anti-anginal therapies, which include secondary nitrate
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lipid lapse, aspirin resistance [9] and coronary microvascu-
lar dysfunction [10].
Therefore, it is of the utmost importance to investigate
the role of complementary and alternative medicines in
the treatment of angina pectoris. Indeed, 64 % of patients
with cardiovascular disease who were surveyed in the
USA tended to use complementary and alternative medi-
cines [11, 12], including Chinese medicines. Chinese med-
icines have been used in therapeutic approaches in East
Asia for over two millennia. In China, Chinese patent
medicines are prevalent and are commonly used as an
alternative to Western medicine [13, 14]. Evidence has
accumulated regarding the efficacy of Chinese medicines
in treating angina pectoris [9, 15–17]. As a Chinese patent
medicine, Danhong injection, which is extracted from
Danshen (Radix Salviae miltiorrhizae) and Honghua
(Flos carthami), is widely prescribed to patients with
coronary heart disease. Danhong injection, the profile
of which has been analyzed using HPLC, is certified as
a Chinese medicinal product by the China Food and
Drug Administration. A number of previous studies,
from the bench to the bedside, have suggested that the
pharmacological mechanisms of Danhong injection might
involve anti-inflammatory activity, anti-atherosclerotic
activity, and the activation of blood circulation [18–22].
Several clinical studies have also demonstrated that
Danhong injection might be an effective and safe treat-
ment option for the management of coronary heart
disease [18, 19].
However, the methodological quality of most previous
studies was assessed to be, in general, low. No critically
appraised evidence, such as a well-designed randomized
controlled trial, is available to provide a high level of evi-
dence to justify the clinical use and recommendation of
Danhong injection. In this study, we will conduct a ran-
domized, multicentre, double-blind, placebo-controlled
trial to investigate the efficacy and safety of Danhong
injection in patients with chronic stable angina. This
trial was registered (NCT01681316) at ClinicalTrials.gov.
Methods/design
Trial design
This study is an adaptive-design, randomized, multicentre,
double-blind, placebo-controlled trial. Patients who meet
the eligibility criteria for chronic stable angina will be ran-
domized into either a Danhong injection or a placebo
group in a 2:1 ratio (Fig. 1, Table 1).
Eligibility criteria
Eligible patients are those who meet all of the following
inclusion criteria and who do not have any of the listed
exclusion criteria.
Diagnostic criteria
1. The diagnostic criteria for chronic stable angina
were determined according to the Chinese
Guidelines for the Diagnosis and Treatment of
Chronic Stable Angina (2007) [23], the ACC/AHA
Guideline Update for the Management of Patients
With Chronic Stable Angina (2002) [24], and the
European Society of Cardiology Guidelines for the
Management of Stable Angina Pectoris [25].
2. Traditional Chinese medicine diagnostic criteria
were determined according to the Guidelines for
Clinical Research of New Drugs of Traditional
Chinese Medicine (2002) [26].
Inclusion criteria
1. Female or male inpatients.
2. Age: 18–70 years.
3. Patients with a clinical diagnosis of chronic stable
angina. Patients must fulfil one of the following
conditions: (a) a history of myocardial infarction and
ST-T changes, (b) stenosis of more than 50 % in at
least one major epicardial coronary artery, as shown
by coronary angiography or computed tomography
angiography, or (c) coronary heart disease confirmed
by radionuclide angiocardiography.
4. Patients with a clinical diagnosis of ‘Xueyu Zheng’
(blood stasis syndrome), which is defined as a score
of at least 15 on the Chinese Medicine Symptom
Scale of ‘Xueyu Zheng’ for angina patients. The
Chinese Medicine Symptom Scale of ‘Xueyu Zheng’
includes the following items: (a) chest pain (0–10);
(b) chest distress (0–10); (c) palpitation (0–5); (d)
purple or dark lips (0–5); (e) purple or dark tongue
(0–5); and (f ) unsmooth pulse (0–5).
5. Patients with moderate angina pectoris, which is
defined as Grade II or III on the Canadian
Cardiovascular Society Angina Grading Scale.
6. Patient is willing to voluntarily participate and to
sign a written informed consent document.
Exclusion criteria
1. Women who are pregnant or lactating or who have
a positive pregnancy test, or women who have a
menstrual period at baseline.
2. Women with childbearing potential who disagree
with using contraception during the treatment
period.
3. Patients with severe complications that would
complicate the condition, as assessed by the
investigator, including liver or renal dysfunction,
severe cardiopulmonary dysfunction, pulmonary
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hypertension, chronic obstructive pulmonary
disease, a history of epilepsy or cerebral
haemorrhage.
4. Patients who were angina-free during the run-in
period without taking any drug.
5. Patients who experienced myocardial infarction or
who were classified as Grade IV on the Canadian
Cardiovascular Society Angina Grading Scale within
the preceding 3 months.
6. Patients with chest pain that is caused by any other
disease (e.g., acute myocardial infarction, severe
neurosis, menopausal syndrome or
hyperthyroidism).
7. Patients with a history of drug-induced bleeding or a
history of bleeding caused by warfarin.
8. Patients with a history of haematopoietic disorder.
9. Patients who have had surgery within the previous
4 weeks or who have a haemorrhagic tendency.
10. Patients who are participating in other trials or
who have participated in other trials within the
past 3 months.
11. Patients with a history of allergy or with a known
or suspected allergy to the study drug.
12. Patients with a known or suspected history of
alcohol or drug abuse within the past 2 years.
13. Patients with a mental disorder.
14. Patients who are unable to participate in the study,
as judged by the investigator.
15. Family members or relatives of the study centre
staff.
Recruitment
Recruitment began in December 2012 and is expected to
end in December 2015. Patients with chronic stable
angina will be screened according to the inclusion and
exclusion criteria, to identify eligible participants. The
Fig. 1 Trial flow chart: DMC, data monitoring committee
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patients will be thoroughly informed regarding the
details of the study and its potential benefits and risks.
Participants will be included only if they meet the inclu-
sion criteria and willingly agree to provide written in-
formed consent. This study is being conducted at dozens
of hospitals across China.
Sample size calculation
According to previous studies [27–32], the proportion of
patients who experienced a clinically significant change
that was defined as at least a 20-point improvement in a
score on the Seattle Angina Questionnaire angina fre-
quency was 30 % after one month of standard conventional
therapy. In this trial, we adopted an adaptive design,
which involved using the statistical sample size calcula-
tion software EAST5.2. It is hypothesized that an in-
crease of at least 10 % is clinically significant for the
Danhong injection group; therefore, the number of sub-
jects required is initially estimated to be 726 (one-sided
test, α = 0.05, β = 0.15). To allow for a 20 % dropout
rate, a total of 870 patients will therefore be recruited.
Because patients will be randomized into the Danhong
injection group or the control group in a ratio of 2:1,
the number of participants in the Danhong injection
group will be 582 and the number in the control group
will be 288. According to the adaptive design, the
sample size can be adjusted based on the results of two
interim analyses, which will be performed after one-
third (288) and two-thirds (582) of the patients have
completed the trial.
Randomization
All eligible patients who consent to participation will be
randomized into either the Danhong injection or the
placebo group in a 2:1 ratio. Randomization will be
conducted using a clinical information management sys-
tem (Brightech, Somerset, USA). This system automatic-
ally randomizes patients and generates a randomization
number with a message noting their assigned treatment.
In addition, randomization will be stratified based on
whether a patient received standard conventional ther-
apy for more than 1 week prior to study initiation.
Blinding
Participants and research personnel will be blinded to
Danhong injection therapy or placebo treatment group
assignments until the study has concluded. Because the
colour of Danhong injection and 0.9 % saline are differ-
ent, the dropping bottles will be wrapped in sealed
shaded bags, and brown infusion devices will be used for
infusion. These procedures will be implemented by two
professional nurses who will be required to sign a confi-
dentiality agreement before study initiation and not to
contact each other. One of the professional nurses will
be in charge of preparing the drugs in a special transfu-
sion room and sealing the infusion bottles with shaded
brown bags. The other nurse will take the prepared
drugs from the transfusion room to the infusion nurse
and supervise the infusion process to ensure that the
allocation of the drugs is blinded to the patients (the
shaded brown bags will not be unwrapped during infu-
sion and will be checked for integrity after infusion).
Interventions
Standard conventional therapy will be provided to all of
the included participants throughout the trial, in strict ac-
cordance with the Chinese Guidelines for the Diagnosis







Day −7 0 7 14 30 60 90
Informed consent × ×
Inclusion or exclusion criteria × ×
Medical history × ×
Medical examination ×
Combined disease treatment × × × × × × ×
Outcome measures:
Proportion of patients who have
a clinically significant change
as defined by Seattle Angina
Questionnaire: angina frequency score
× × × ×
Symptom questionnaire of traditional
Chinese medicine
× × × × × ×
The other four Seattle Angina
Questionnaire scales
× × × × × ×
Frequency of anginal attack
per week
× × × × × × ×
Canadian Cardiovascular
Society grade
× × × × × ×
Consumption of short-acting nitrates × × × × × × ×
Electrocardiogram × × × × × ×
Serum lipids × ×
High-sensitivity C-reactive protein × ×
Platelet aggregation rate × ×
New-onset major vascular events ×
Overall mortality ×
Incidence of severe haemorrhage ×
Incidence of moderate haemorrhage ×
Adverse and serious adverse events × × × × ×
Exercise tolerance test (if necessary
after 1st interim analysis)
× ×
Profiles of micro-RNA in 60 patients
in certain centres
× × ×
Profiles of mRNA in 60 patients in
certain centres
× × ×
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and Treatment of Chronic Stable Angina (2007) [23].
Standard conventional therapy includes:
(a) Antiplatelet agents: aspirin (75–100 mg, once per
day) or clopidogrel (if the patient is intolerant to
aspirin). Patients with a history of percutaneous
coronary intervention will be prescribed both of
these agents.
(b) Lipid-lowering agents (statins): atorvastatin
(10–20 mg, once per day) or simvastatin
(20–40 mg, once per day).
(c) Anti-angina agents: β-blockers (metoprolol 50–
200 mg, once per day, or analogous agents);
long-acting nitrates (isosorbide mononitrate
40–60 mg, once per day); or calcium channel
blockers (amlodipine 5–20 mg, once per day).
(d) Patients with diabetes and hypertension will be
advised to take angiotensin-converting enzyme
inhibitors or angiotensin-receptor blockers
(e.g., lisinopril 10–20 mg, once per day, or losartan
50 mg, once per day) as a secondary preventive
measure for chronic stable angina.
All of these basic treatments will be recorded in detail
in the patients’ medical records as well as in their case
report forms.
Participants in the Danhong injection group will be
treated using Danhong injection (40 ml per day) plus
0.9 % normal saline (250 ml intravenously per day),
while participants in the placebo group will be treated
using placebo (0.9 % normal saline, 40 ml per day) plus
0.9 % normal saline (250 ml intravenously per day).
Participants who received standard conventional therapy
for more than 1 week prior to study initiation will be
randomized directly into one of the groups; otherwise, a
run-in period of 1 week of standard conventional ther-
apy will be performed before randomization. All of the
included patients will undergo a 2-week treatment regi-
men and a 76-day follow-up period.
Patients will be instructed to take a nitroglycerin tablet
(0.5 mg per tablet, provided by Beijing Yimin Pharma-
ceutical Co., Ltd.) in case of an angina attack, and this
dose can be repeated approximately every 5 minutes
until the angina is relieved. If the angina persists after
three doses, the patient should be transported to hos-
pital immediately for further medical treatment. Patients
will be asked to record the details of administration
times, the number of doses and the dosages of nitrogly-
cerin in a patient diary, which will be collected by the
investigators at a subsequent study visit.
Concomitant medications that are deemed necessary to
manage any serious underlying disease will be allowed dur-
ing the study and should be recorded in a patient’s medical
records and case report forms. However, participants are
not allowed to take any other Chinese herbal medicines
or Chinese patent medicines that have the effect of
promoting blood circulation or removing blood stasis
throughout the study period.
Quality control for the intervention
All of the staff, including the operators, investigators,
data collectors and analyzers, are to be strictly trained.
In each clinical centre, special transfusion rooms should
be established and staffed with professional nurses. For
outpatient appointments, physicians (investigators) must
fill out medical record cards and medications record
cards in a timely manner.
To abide by the blinding principle, the placebo oper-
ation must be performed by two professional nurses
who were required to sign a confidentiality agreement to
commit to not having contact with each other. One of
the professional nurses will be in charge of drug prepar-
ation and will never be allowed to have contact with the
investigators, analyzers, sponsors or organizers of the
trial throughout the trial, and the other will be respon-
sible for sending prepared drugs to patients.
Outcome measurements
The primary outcome is the proportion of patients with
a clinically significant change, which is defined as show-
ing at least a 20-point improvement on the Seattle
Angina Questionnaire angina frequency score on day 30.
The Seattle Angina Questionnaire is a 19-item question-
naire that quantifies physical limitations due to angina,
any recent change in the severity of angina, the fre-
quency of angina, satisfaction with treatment and quality
of life. The total score can range from 0 to 100, and
higher scores indicate a better health status [31].
The secondary outcome measures include:
a) The total score of symptoms in a questionnaire
related to traditional Chinese medicine;
b) The proportion of patients who experience clinically
significant changes in the other four Seattle Angina
Questionnaire domains;
c) The frequency of anginal attacks per week;
d) Angina grade, according to the Canadian
Cardiovascular Society Angina Grading Scale;
e) Consumption of short-acting nitrates;
f ) Changes in electrocardiogram results;
g) Changes in serum lipid levels, high-sensitivity
C-reactive protein levels and the rate of platelet
aggregation.
The safety of Danhong injection will be evaluated by
the incidence of new-onset major vascular events within
90 days, the overall mortality within 90 days, the
incidence of severe haemorrhages within 90 days, the
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incidence of moderate haemorrhages within 90 days,
and the incidence of adverse and serious adverse events.
In addition, other pre-specified outcome measures,
including changes from baseline in an exercise tolerance
test performed on day 14 in 290 patients for the first
interim analysis and changes in the micro-RNA and
mRNA profiles of 60 patients selected at the Chinese
PLA General Hospital and Xuanwu Hospital Capital
Medical University. An overview of the measurements
collected for data is shown in Table 1.
After each interim analysis, the data monitoring com-
mittee will determine whether it is necessary to continue,
modify or terminate the collection of these outcome data.
Safety and adverse events
An adverse event is defined as any unexpected and un-
comfortable medical occurrence in a patient or clinical
investigation subject being administered a pharmaceut-
ical product. The event does not necessarily have to have
a causal relationship with the study treatment.
A serious adverse event is defined as any adverse event
that fulfils at least one of the following criteria:
 Is fatal;
 Is a life-threatening event;
 Leads to inpatient hospitalization or the
prolongation of existing hospitalization;
 Leads to persistent or significant disability or
incapacity;
 Leads to a congenital anomaly or birth defect;
 Is medically significant or requires intervention to
prevent one or more of these outcomes.
All adverse events that occur in the clinical study must
be recorded on the case report form and must include
the following contents: type, intensity, emergence time,
duration, action taken and process. The relationship
between the adverse event and the studied drug must be
assessed and recorded by the investigator, in consider-
ation of complications and the combined use of drugs.
If adverse events occur, the investigator will determine
whether the participant should withdraw from the study,
according to the condition of the patient, and follow-up
procedures will be performed and recorded in detail.
Safety issues will also be reviewed and combined with
incidence data and data concerning the treatment of the
patient, to determine whether the adverse events are
associated with the investigated drug.
For serious adverse events, the investigator must im-
mediately take necessary measures, report to the princi-
pal investigator and the ethics committee, and place a
record on the case report form including a signature
and the date. The classification of the severity of ad-
verse events and their relationship to the studied drug
will be conducted according to the methods in our
previous study [33].
Interim analysis
Because this is an adaptive trial, two interim analyses are
prospectively planned, and these will be performed in a
blinded manner after one-third and two-thirds of the
patients, respectively, have completed the trial. The stat-
istical results of the interim analyses will be relayed to
the data monitoring committee, who will decide on the
re-estimation of sample size and determine whether any
subsequent modifications must be made to the trial
protocol. Because the two interim analyses may lead to
an increased possibility of a type I error, we will apply
the Lan–DeMets alpha spending function with an
O’Brien–Fleming boundary to adjust the results.
Data collection and management
This trial is divided into three phases: a run-in period, a
treatment period and a follow-up period. An overview of
the study visits and data collection is provided in
Table 1.
All data will be recorded by trained clinical investiga-
tors using standardized electronic case report forms and
Brightech clinical information management systems
(Brightech, Somerset, NJ, USA). The accuracy and reli-
ability of the data will be ensured by the study monitor,
who will verify and cross-check the electronic case
report forms against the investigator’s records (source
document verification), using the maintenance of a drug-
dispensing log by the investigator. Front-end checks in the
electronic case report forms and back-end checks in the
clinical information management system will be used as
a validation check of the data. If there are any discrep-
ancies in the electronic case report forms, the results
will be sent to the investigator for resolution. To facili-
tate analysis of the data, the treatment code will be
released to the statisticians. The results of the analysis
must not be released with individual identification of
the subjects until the database is closed.
To ensure the effectiveness and integrity of the trial
design, three committees have been established by the
multicentre trial coordination group: the clinical trial
guidance committee, the data monitoring committee
(also known as the data and safety monitoring board)
and the outcome evaluation committee. The first com-
mittee is responsible for the study design and the im-
plementation process. The data monitoring committee
will supervise the integrity and accuracy of data collec-
tion to control its quality. The outcome evaluation
committee will evaluate key outcomes (including out-
come measurements and adverse events) based on their
clinical expertise.
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Statistical analysis
Statistical analysis will be performed using Statistical
Analysis System version 9.1 (SAS Institute Inc, Cary,
NC, USA) statistical software packages. Most outcome
measurements (except the micro-RNA and mRNA pro-
files) will be analyzed using full analysis sets and per-
protocol sets according to intention-to-treat analysis.
Safety analysis will be performed in a safety set, which is
defined as a subset of subjects who were randomized
and who received at least one treatment.
The statistical analysis will include the distribution of
subjects, baseline characteristics of participants, compli-
ance and concomitant medication, efficacy analysis and
safety analysis. For parametric tests, we will describe the
results using the mean (standard deviation), maximum,
minimum, median and non-parametric test median
(quartile deviation). Categorical data will be described as
absolute values and proportions.
Quantitative data will be compared using analysis of vari-
ance (ANOVA) and t tests. Paired t tests will be used to
analyze significant differences between pre- and post-
treatment time points. Two-sample t tests will be employed
for comparisons between treatment groups. After ANOVA,
we will then use Student–Newman–Keuls significance
tests for pairwise comparisons. Enumeration data will
be analyzed using χ2 tests, Cochran–Mantel–Haenszel
χ2 tests, Fisher’s exact tests or Wilcoxon rank tests; χ2
tests will be used for nominal categorical data and rank
sum tests will be used for ordinal categorical data. Ana-
lysis of covariance (ANCOVA) will be used to control
potential confounding variables. Significance tests will
be two-tailed, with a statistical probability of P <0.05.
Distribution of subjects
Analytical statistics will be calculated to estimate the
difference in the number of participants who have com-
pleted or who have been withdrawn from the trial between
groups.
Baseline characteristics
Baseline characteristics in each group will be analyzed
using descriptive statistics, including means or medians
for continuous variables and percentages for categorical
variables.
Compliance and concomitant medication
Compliance analysis will be based on full analysis sets,
and analysis of concomitant medications will be based
on safety sets.
Efficacy analysis
Primary and secondary efficacy parameters will be ana-
lyzed. Any factors impacting efficacy, such as age and
sex, should be taken into account as covariants, and an
ANCOVA model, Cox’s proportional hazards regression
model, or logistic regression model will be used to assess
treatment effects for these factors. In addition, study
participants will be classified according to whether they
have been treated with long-acting nitrates and will then
be enrolled into a study stratum. We will conduct
stratified analysis, and each stratum will be analyzed
separately.
Safety analysis
Safety will be analyzed in terms of the incidence of new-
onset major vascular events within 90 days, the overall
mortality within 90 days, the incidence of severe hae-
morrhages within 90 days, the incidence of moderate
haemorrhages within 90 days, and adverse and seriously
adverse events.
Ethics
This trial has been approved by local institutional ethics
committees (the ethics committees of the Institute of
Basic Clinical Research, China Academy of Chinese
Medical Sciences and of Chinese PLA General Hospital).
This trial will be conducted in adherence to the Declar-
ation of Helsinki (Edinburgh 2000). Informed written
consent will be required of all participants.
Discussion
It is widely accepted that a randomized controlled trial
is the gold standard for evaluating the clinical efficacy
and safety of a Chinese medicine and for providing
critical evidence to develop and guide treatment strat-
egies. However, it has been suggested, controversially,
that the principle of a randomized controlled trial goes
against the doctrine of traditional Chinese medicine as
personalized medicine. There are several drawbacks in
the methodological quality of most Chinese medicine
trials [34]. These include inadequate randomization, a
lack of double blinding, non-placebo controls and in-
complete outcome data. All of these lead to various
biases that can weaken the credibility of the evidence.
There are several strengths in the methodological de-
sign and interventions described in this study. First, this
is the first rigorously designed randomized controlled
trial to evaluate the efficacy and safety of Danhong injec-
tion for chronic stable angina. Although a number of tri-
als on Danhong injection have been published, there is a
lack of well-designed trials that examine the efficacy of
Danhong injection for the management of chronic stable
angina. In this study, a central online randomization sys-
tem is used for random sequence generation and alloca-
tion concealment, which might avoid potential selection
bias. The blinding of both the participants and the study
personnel and the blinding of outcome assessments are
used to reduce the potential for performance bias and
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detection bias, respectively. Most previously published
randomized controlled trials lack a placebo control. We
understand that some critical characteristics of com-
monly used herbal medicines and Chinese patent medi-
cines, such as colour, appearance, odour, and other
properties, restrict the wide application of placebo con-
trols in Chinese medicine studies. However, placebo
control is strictly implemented in our study. The dosage
form of an injection has a remarkable placebo effect. We
employ wrapped dropping bottles and brown transfusion
devices to facilitate a placebo control. Thus, the treat-
ment appears to be identical between the Danhong in-
jection and placebo groups. We assume that a potential
placebo effect can be excluded in our study. An add-on
study design is also applied in this trial, which can be
summarized as an ‘A + B versus B’ model. In this model,
participants are randomized to receive either interven-
tion A combined with intervention B or intervention B
alone. This method is widely used in Chinese medicine
studies, where Chinese medicine is added to a conven-
tional treatment [35]. However, the effect of Chinese
medicine therapy will be exaggerated if no rigorous
control is used to exclude a placebo effect. In view of
this, we designed and implemented the study in a sci-
entific, strict and cautious manner to provide reliable
evidence regarding the use of Danhong injection as a
complementary therapy for treating chronic stable an-
gina. Finally, in this trial, we also adopted an adaptive
design, which is defined as a study that includes a pro-
spectively planned opportunity for the modification of
one or more specified aspects of the study design and
hypotheses based on the analysis of accumulating data
(usually interim data) from subjects in the study [36].
This method will make the study more efficient (e.g.,
have a shorter duration or include fewer patients) and
is more likely to demonstrate an effect of the drug if
one exists [36, 37].
Second, the outcome measures in our study are
patient-centred. Currently, the assessment of treatment
efficacy is being transformed from a traditional doctor-
reported outcome model to a patient-reported outcome
model, indicating that more attention is being paid to
the quality of life of the patients and the relief of symp-
toms. Guidelines for the management of chronic stable
angina also recommend that the treatment goal should
include the relief of symptoms [3]. Traditional Chinese
medicine has been suggested as a promising option for
alleviating symptoms and improving quality of life.
Therefore, we use changes in Seattle Angina Question-
naire scores and traditional Chinese medicine syn-
drome scores as our outcome measures because they
both focus on patient symptoms. This will help us to
provide reliable and convincing evidence for the effi-
cacy of Danhong injection.
Finally, another key point of this study is that the
study drug has substantial therapeutic value in real-
world clinical practice. It has been proposed that blood
stasis syndrome (Xueyu Zheng) is the most common
type of chronic stable angina [9]. A recently published
review also demonstrated that Chinese patent medicines
that promote blood circulation and remove blood stasis,
when used as adjunctive treatments for routine anti-
anginal therapy, play an active role in reducing the
incidence of primary endpoint events, decreasing anginal
attack rates, and improving electrocardiogram results
[9]. Danhong injection is a certified Chinese medicinal
product that is extracted from Danshen (Radix Salviae
miltiorrhizae) and Honghua (Flos carthami). According
to the basic theory of Chinese medicine, Danhong injec-
tion can produce a remarkable curative effect by pro-
moting blood circulation and removing blood stasis.
Moreover, numerous studies, both in vivo and in vitro,
have validated the vascular protective effects of Danhong
injection [18–22, 31, 38]. Based on the theoretical and
clinical evidence mentioned previously, Danhong injec-
tion is regarded as a promising therapeutic option for
the treatment of chronic stable angina.
However, there are also several limitations in this
study. One of the major drawbacks lies in the lack of
assessment of Danhong injection’s long-term effects on
primary outcome measures. In our study, the follow-up
period is only 76 days, which is relatively short. Owing
to the short length of the follow-up period and limita-
tions on our budget, the potential role of Danhong injec-
tion in reducing major vascular events and overall
mortality over the long term will remain unknown. In
addition, although an add-on study design and a placebo
control will be applied in our study to interpret the
complementary effect of Danhong injection, we will still
be unable to draw a definite conclusion over whether
Danhong injection can serve as an alternative therapy
for chronic stable angina because we do not use a ‘head-
to-head’ design. Therefore, well-designed randomized
controlled trials that compare Danhong injection with
conventional anti-anginal therapies and that have longer
follow-up periods are needed in the future.
Trial status
The study began recruiting patients in 2012. The trial is
currently recruiting patients.
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